| ARTICLE |
|
| Year : 2004 | Volume
: 9
| Issue : 2 | Page : 72-76 |
|
|
Therapeutic benefits of maximum androgen blockade and tolerability of bicalutamide in patients with advanced prostate cancer
AE Aghaji1, JO Ohaju-Obodo2, DN Osegbe3, HN Mbibu4, H Maitama4
1 Department of Surgery, University of Nigeria Teaching Hospital, Enugu, Nigeria
2 Medical Department, AstraZeneca, P. O. Box 3560, Ikeja, Lagos, Nigeria
3 Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria
4 Department of Surgery, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria
Correspondence Address:
A E Aghaji
Urology Unit, Department of Surgery, University of Nigeria Teaching Hospital, Enugu
Nigeria
 Source of Support: None, Conflict of Interest: None
|
|
|
Aim: To assess the therapeutic benefits of Maximum Androgen Blockade and the Tolerability of Bicalutamide, an oral non-steroidal anti-androgen in patients with advanced prostate cancer.
Patients and Methods: A total of forty-nine(49) male patients aged between 42 and 84 years with tumour grades T2, T3 and T4 were enrolled in a multi-centre clinical trial to receive bicatutamide 50mg daily following surgical castration. Patients were assessed for disease status, adverse events and quality of life.
Results: Thirty-three (33) patients completed the study and had therapy for 48 weeks, 90.9% of whom had complete response while the quality of life due to urinary symptoms was also markedly improved. The profile of adverse events was mild.
Conclusion: Bicalutamide given as a daily dose of 50mg in combination with surgical castration is a well tolerated therapy and has therapeutic benefits in African patients with advanced prostate cancer.
|
|
|
|
| [PDF]* |
|
 |
|
